1. Scrip
  2. >>Focus On Asia
  3. >>India

Is Dexamethasone The Next HCQ For Indian Pharma?

Zydus Cadila, Wockhardt, Cadila, Cipla Could Gain

 
• By Vibha Ravi

While the jury is still out on dexamethasone being the new hero in the fight against COVID-19 after the hype around hydroxychloroquine has died down, Indian pharma is watching developments closely. Gains of companies like Zydus Cadila, Wockhardt, Cadila and Cipla in the domestic market will be constrained by price caps while any increase in exports will depend on emergency use authorizations

Is Dexamethasone The Next Money-spinner For Indian Companies? • Source: Shutterstock

COVID-19 is turning out to be like the board game snakes and ladders, with the drugs seen as potential treatments being the players and clinical trials the snakes.

After the UK Recovery trial, run by the University of Oxford, showed lowered mortality in severe cases of COVID-19, dexamethasone has snatched the top spot from previous big hope remdesivir,

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from India

More from Focus On Asia